Suven Life Sciences

₹274.30As of Sun 8 Nov 2026, 12:00 UTC

NSE:SUVENHealthcare

Country India

PE (Fwd) —

TSR 10Y CAGR 4.68%

Div yield —

ROE —

Drug Manufacturers (Specialty & Generic)

Beta (5Y) 0.95

PE TTM —

TSR TTM 38.85%

Mkt cap ₹78.96B

ROIC —

SE Grade™

—

Value

Quality

Moat

—

1Y Price

Reference

₹309

12.66%

(99.24%)

Price above Reference Value

FY23

FY24

FY25

FY26

Earnings per share₹

(6.63)

(4.82)

(7.37)

(12.13)

26.72%

27.34%

(52.93%)

(64.60%)

Revenue₹M

135.9

116.9

66.56

71.15

13.76%

(13.99%)

(43.08%)

6.89%

TTM

FYE 31 Mar INR

FY2017

FY2018

FY2019

FY2020

FY2021

FY2022

FY2023

FY2024

FY2025

FY2026

FY2027E

Trend

10Y

Peers

71.15

Revenue₹M

—

119.5

135.9

116.9

66.56

71.15

70.54

(12.16%)

6.89

Revenue growth%

—

13.76

(13.99)

(43.08)

6.89

(0.85)

(3.55)

—

100

91.12

Gross margin%

—

79.64

95.84

92.95

88.71

91.12

91.63

91.12

(4072.38)

Operating margin%

—

(1056.14)

(971.27)

(1148.49)

(2572.07)

(4072.38)

(100.00)

(1148.49)

(3884.13)

Net margin%

—

(1020.82)

(869.95)

(898.62)

(2415.11)

(3884.13)

(100.00)

(1020.82)

—

P/E ratio (avg)x

—

EV/EBITx

—

FCF yield (avg)%

—

FCF margin%

—

FCF / Net incomex

—

ROIC%

—

Return on equity%

—

Return on assets%

—

(12.13)

EPS₹

—

(9.05)

(6.63)

(4.82)

(7.37)

(12.13)

(0.31)

—

(64.60)

EPS growth%

—

26.72

27.36

(52.98)

(64.60)

97.45

(13.13)

—

Bookvalue per sh₹

—

FCF per share₹

—

Dividend per sh₹

—

1.00

—

Div yield (avg)%

—

1.07

—

1.07

—

Payout ratio%

—

227.8

Shares (diluted)M

—

134.8

178.3

218.1

227.8

◌227.8

14.02%

(4.44)

Buyback yield%

—

(32.29)

(22.31)

—

(4.44)

◌—

(13.38)

—

D/E ratiox

—

62.48

Enterprise value₹B

—

12.56

12.54

18.52

27.94

46.59

62.48

38.78%

—

LT debt₹M

—

Peers (US$802.3M)

Cap (US$)

Aarti Pharmalabs…

898.1M

41.23x

Bliss GVS Pharma…

684.0M

48.73x

FDC Limited

676.6M

20.29x

Anhui Wanbang Pharmace…

803.8M

1,371x

Capital

TTM

10Y

Leveragex

—

EBIT/Intx

(1,836)

(847.8)

Own earn%

—

Sh yield%

(4.44)

(13.38)

Owners

Insiders/Inst%

—

Short interest%

—

SBC / revenue%

—

Record

10Y

Profitable years

0/5

Revenue growth years

2/4

EPS growth years

2/4

Dividend streakyrs

Op margin range%

−4072–−971

$1 testx

—

Incr. ROIC%

—

Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, develops novel therapeutics for central nervous system disorders and unmet needs in mental health in India, the United States, Europe, and internationally.

Growth vs revenue

Latest

Trend

4Y CAGR

Rel growth

Revenue

₹71.15M

(12.16%)

1.00×

Cost of revenue

₹6.318M

(28.61%)

0.44×

Operating expenses

₹2.962B

21.54%

3.67×

Revenue by region

No breakdown available

Reinvestment returns

No breakdown available